The drug increases IFN-γ production by NK cells isolated from MM patients by augmenting nanoscale rearrangements in cortical actin at the immunological synapse and increasing the proportion of the synapse predicted to be penetrable to IFN-γ vesicles after ligation of the activating receptor CD16 [53]. The gene discussed is IFNG; the disease is Miyoshi myopathy.